Features of kidney structural changes in IgA-nephropathy with isolated detection of IgA class antibodies to deamidated gliadin peptides in the serum
https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.341
Abstract
Backgrоund. Immunoglobulin A nephropathy (IgA-N) is a common form of chronic glomerulonephritis. Its basis is the accumulation of IgA immune complexes in the glomeruli, associated with impaired glycosylation of the IgA molecule. Exogenous antigens, such as gluten, play an important role in the development of the disease. It has been experimentally confirmed that oral immunization with gluten induces mesangial IgA deposits, and a gluten-free diet can improve the course of nephropathy, indicating the significance of the enterorenal axis in the pathogenesis of IgA-N.
Objective: To study structural changes in renal tissue in IgAN patients and to evaluate the clinical and diagnostic significance of IgA antibodies to deamidated gliadin peptides (anti-DGP IgA) in the blood serum.
Material and methods. The study involved 105 patients aged 18 to 64 years diagnosed with IgAN based on a lifetime nephrobiopsy with morphological examination according to the Oxford classification. Patients were divided into two groups: the main group (n=20) included IgAN patients with detected anti-DGP IgA, and the control group (n=85) included IgAN patients seronegative for anti-DGP IgA, IgA antibodies to tissue transglutaminase, and to endomysium.
Results. When comparing fibrous-sclerotic changes, no statistically significant intergroup differences were obtained. However, a clear trend of predominance of irreversible light-optical changes within the area of the nephrobiopsy specimen was noted in patients of the main group compared to the control group: 82.4% and 56.9%, respectively (p=0.059).
Conclusion. The obtained results reflect a high frequency of irreversible fibrous-sclerotic changes in the nephrobiopsy in patients with IgAN and anti-DGP IgA in the blood serum. Timely detection of anti-DGP IgA can improve the ability to predict the outcome of the disease and optimize therapeutic strategies.
About the Authors
D. I. Korabelnikov
Moscow Haass Medical and Social Institute
Russian Federation
Russian Federation
Daniil I. Korabelnikov, PhD, Assoc. Prof.
Scopus Author ID: 7801382184.
5 2nd Brestskaya Str., Moscow 123056
M. E. Mantsaeva
Moscow Haass Medical and Social Institute; Branch Clinical and Diagnostic Center of PJSC Gazprom; Main Clinical Hospital of the Ministry of Internal Affairs of the Russian Federation
Russian Federation
Russian Federation
Maria E. Mantsaeva
5 2nd Brestskaya Str., Moscow 123056;
16 Nametkina Str., Moscow 117420;
35 Narodnogo Opolcheniya Str., Moscow 123060
A. G. Borisov
Moscow Haass Medical and Social Institute; Russian Medical Academy of Сontinuous Professional Education
Russian Federation
Russian Federation
Alexey G. Borisov, PhD, Assoc. Prof.
5 2nd Brestskaya Str., Moscow 123056;
2/1 bldg 1, Barrikadnaya Str., Moscow 125993
References
1. Glomerular diseases: immunoglobulin A nephropathy. Clinical guidelines. 2024. Aailable at https://cr.minzdrav.gov.ru/preview-cr/894_1 (in Russ.) (accessed 05.04.2025).
2. Rollino C., Vischini G., Coppo R. IgA nephropathy and infections. J Nephrol. 2016; 29 (4): 463–8. https://doi.org/10.1007/s40620-016-0265-x.
3. Emancipator S.N., Gallo G.R., Lamm M.E. Experimental IgA nephropathy induced by oral immunization. J Exp Med. 1983; 157 (2): 572–82. https://doi.org/10.1084/jem.157.2.572.
4. Coppo R., Mazzucco G., Martina G., et al. Gluten-induced experimental IgA glomerulopathy. Lab Invest. 1989; 60 (4): 499–506.
5. Papista C., Lechner S., Ben Mkaddem S., et al. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction. Kidney Int. 2015; 88 (2): 276–85. https://doi.org/10.1038/ki.2015.94.
6. Fornasieri A., Sinico R.A., Maldifassi P., et al. IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger's disease). Br Med J (Clin Res Ed). 1987; 295 (6590): 78–80. https://doi.org/10.1136/bmj.295.6590.78.
7. Laurent J., Branellec A., Heslan J.M., et al. An increase in circulating iga antibodies to gliadin in iga mesangial glomerulonephritis. Am J Nephrol. 1987; 7 (3): 178–83. https://doi.org/0.1159/000167460.
8. Coppo R., Roccatello D., Amore A., et al. Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol. 1990; 33 (2): 72–86.
9. Costa S., Currò G., Pellegrino S., et al. Case report on pathogenetic link between gluten and IgA nephropathy. BMC Gastroenterol. 2018; 18 (1): 64. https://doi.org/10.1186/s12876-018-0792-0.
10. Cattran D.C, Coppo R, Cook H.T., et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76 (5): 534–45. https://doi.org/10.1038/ki.2009.243.
11. Coppo R. The gut-renal connection in IgA nephropathy. Semin Nephrol. 2018; 38 (5): 504–12. https://doi.org/10.1016/j.semnephrol.2018.05.020.
12. Almroth G., Axelsson T., Müssener E., et al. Increased prevalence of anti-gliadin IgA-antibodies with aberrant duodenal histopathological findings in patients with IgA-nephropathy and related disorders. Ups J Med Sci. 2006; 111 (3): 339–52. https://doi.org/10.3109/2000-1967-060.
13. Mantsaeva M.E., Korabelnikov D.I., Borisov A.G. Clinical and diagnostic significance of isolated detection of IgA antibodies to deamidated gliadin peptides in IgA nephropathy patients. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2025; 18 (1): 62–70 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.304.
14. Ots M., Uibo O., Metsküla K., et al. IgA-antigliadin antibodies in patients with IgA nephropathy: the secondary phenomenon? Am J Nephrol. 1999; 19 (4): 453–8. https://doi.org/10.1159/000013497.
15. Ankelo M., Kleimola V., Simell S. Antibody responses to deamidated gliadin peptide show high specificity and parallel antibodies to tissue transglutaminase in developing coeliac disease. Clin Exp Immunol. 2007; 150 (2): 285–93. https://doi.org/10.1111/j.1365-2249.2007.03487.x.
16. Hill I.D., Dirks M.H., Liptak G.S., et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005; 40 (1): 1–19. https://doi.org/10.1097/00005176-200501000-00001.
17. Dictionary of terms and abbreviations used in evidence-based medicine. Evidence-Based Cardiology. 2016; 9 (2): 39–42 (in Russ.).
18. Nguyen Q.D., Moodie E.M., Desmarais P., et al. Appraising clinical applicability of studies: mapping and synthesis of current frameworks, and proposal of the FrACAS framework and VICORT checklist. BMC Med Res Methodol. 2021; 21 (1): 248. https://doi.org/10.1186/s12874-021-01445-0.
19. Mantsaeva M.E., Korabelnikov D.I., Borisov A.G. Method for determining the probability of detection of iga antibodies to deamidated gliadin peptides in patients with iga nephropathy. Bulletin of Pirogov National Medical & Surgical Center. 2025; 20 (3): 96–100 (in Russ.). https://doi.org/10.25881/20728255_2025_20_3_96.
Review
For citations:
Korabelnikov D.I., Mantsaeva M.E., Borisov A.G. Features of kidney structural changes in IgA-nephropathy with isolated detection of IgA class antibodies to deamidated gliadin peptides in the serum. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.341
Views:
10
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 